Kezar Life Sciences
2015
FOUNDED
PUBLIC
STATUS
21-30
EMPLOYEES
KZR
STOCK SYMBOL
$17.00
SHARE PRICE
(As of Thursday Closing)
Description
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and protein secretion program.
Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 4000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Kezar Life Sciences’s full profile, request a free trial.
Kezar Life Sciences Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $14.77 - $36.33 | $325M | $18.27 | -$3.89 | 97K | 19.1M |
Kezar Life Sciences Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 231,729 | 477,852 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (27,043) | (24,036) | (8,574) | (8,836) |
| Net Income | (25,862) | (23,167) | (8,517) | (8,990) |
| Total Assets | 113,056 | 114,682 | 54,222 | 11,424 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kezar Life Sciences Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Kezar Life Sciences‘s full profile, request access.
Request full access to PitchBookKezar Life Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Kezar Life Sciences‘s full profile, request access.
Request full access to PitchBookKezar Life Sciences Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MacroGenics | Formerly VC-backed | Rockville, MD | 000 | 00000 | 00000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | San Jose, CA | 00 | 000.00 | 00000000 | 000.00 |
| 0000 0000000000 | Venture Capital-Backed | Beijing, China | 000.00 | 00000000000 | 000.00 | |
| 000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 0 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | Diepenbeek, Belgium | 0 | 000.00 | 00000000000 | 000.00 |
Kezar Life Sciences Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Kezar Life Sciences‘s full profile, request access.
Request full access to PitchBookKezar Life Sciences Executive Team (6)
You’re viewing 5 of 6 executives. Get the full list »Kezar Life Sciences Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Bihua Chen | Cormorant Asset Management | Board Member | 000 0000 | |
| Franklin Berger | Self | Board Member | 000 0000 | |
| Gerald Chan Ph.D | Morningside Group | Board Member | 000 0000 | |
| Graham Cooper | Self | Board Member | 000 0000 | |
| Jason Dinges Ph.D | Morningside Group | Board Member | 000 0000 |